生产企业：Halda Therapeutics
HLD-0915 is an innovative bifunctional small molecule therapy developed by Halda Therapeutics and designed to selectively target prostate cancer tumor cells. It has received FDA fast track designation for the treatment of metastatic castration-resistant prostate cancer. In a first-in-human Phase 1/2 study of HLD-0915 in metastatic castration-resistant prostate cancer, 31% of all 31 treated patients achieved a response, and the treatment showed a favorable safety profile across all dose levels tested (12.5 mg, 25 mg, 50 mg, and 100 mg once daily).
HLD-0915 is an innovative bifunctional small molecule therapy developed by Halda Therapeutics and designed to selectively target prostate cancer tumor cells. It has received FDA fast track designation for the treatment of metastatic castration-resistant prostate cancer. In a first-in-human Phase 1/2 study of HLD-0915 in metastatic castration-resistant prostate cancer, 31% of all 31 treated patients achieved a response, and the treatment showed a favorable safety profile across all dose levels tested (12.5 mg, 25 mg, 50 mg, and 100 mg once daily).
Metastatic castration-resistant prostate cancer (mCRPC). HLD-0915 is being evaluated in patients with metastatic prostate cancer who have progressed on prior systemic therapy.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
